<DOC>
	<DOCNO>NCT01684761</DOCNO>
	<brief_summary>The purpose study determine whether Tcelna ( imilecleucel-T , autologous T-Cell Immunotherapy ) effective treatment secondary progressive multiple sclerosis ( SPMS ) .</brief_summary>
	<brief_title>Study Tcelna ( Imilecleucel-T ) Secondary Progressive Multiple Sclerosis</brief_title>
	<detailed_description>Subjects whose myelin reactive T-cell identify EPA randomize provide blood manufacture Tcelna . Approximately 5 week receipt subject 's whole blood procurement , subject receive either Tcelna placebo complete baseline assessment receive study treatment Weeks 0 , 4 , 8 , 12 , 24 ( Visits 3-7 ) , total 5 dos year one . Approximately one month prior Week 52 visit second blood procurement perform subject receive second series treatment receive first year study schedule . Subjects evaluate change disability cognitive function every 3 month , radiographic change annually .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Autoimmune Diseases Nervous System</mesh_term>
	<criteria>Diagnosed MS define modify McDonald criterion SPMS define relapsingremitting disease recent progression MSrelated neurological deficit EDSS score 3.0 6.0 , inclusively Presence myelin reactive Tcells Diagnosed primary progressive MS Treatment betainterferon , glatiramer acetate dimethyl fumarate 30 day prior screen Treatment ACTH , overthecounter prescription corticosteroid 60 day prior screen Treatment IVIG , plasmapheresis cytopheresis 90 day prior screen Treatment mitoxantrone , teriflunomide , fingolimod , natalizumab , azathioprine , cyclosporine , methotrexate mycophenolate mofetil 1 year prior baseline Any prior treatment cladribine , cyclophosphamide , total lymphoid irradiation , T cell T cell receptor product , therapeutic monoclonal antibody , except natalizumab Previous treatment MS investigational drug 1 year prior screen All nonMS investigational drug must minimum washout 30 day prior screen 5 halflives , whatever long period time . HIV hepatitis infection History cancer Any significant medical condition , opinion investigator , could cause CNS tissue damage limit repair .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Multicenter Study</keyword>
	<keyword>Randomized Controlled Trial</keyword>
	<keyword>Individualized Medicine</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Myelin Proteins</keyword>
	<keyword>Biological Agents</keyword>
</DOC>